4:35 AM
Feb 27, 2018
 |  BC Extra  |  Financial News

Synthetic biology play Senti debuts with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise Associates (NEA). 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Co., Nest.Bio, Omega Funds, Goodman Capital and LifeForce Capital also participated.


Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >